Perelman School of Medicine at the University of Pennsylvania

Gelfand Clinical Research Lab

  • Team Outing October 2019

  • FDG-PET/CT results after 12 weeks of NB-UVB phototherapy

  • Clinical Image and FDG-PET/CT results after 12 weeks of NB-UVB phototherapy

  • The Journal of the American Medical Association (JAMA), October 2006

  • BMJ, October 2013


The Gelfand Clinical Research Lab designs and conducts clinic-based and population-based observational studies and interventional and translational clinical trials in common and rare skin diseases. Dr. Gelfand and his team focus on pharmacoepidemiology, patient centered outcomes and effectiveness research, psychometrics and instrument/diagnostic test development, and human translational studies aimed at the development of novel treatment approaches and further understanding of disease pathogenesis.  A major goal of the Gelfand Clinical Research Program is to improve psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, cardiovascular disease and mortality.

Current research projects include:

-  Cardiovascular Disease Prevention for Psoriasis and Psoriatic Arthritis (CP3), the CP3 Study aims to shift screening for, and management of, dyslipidemia to specialists who mostly care for patients with psoriasis with a focus on use of statins. CP3 includes a multi-disciplinary and institutional team of investigators led by Dr. Gelfand, MD,MSCE and Dr. Nehal Mehta, MD, MSCE and funded by the National Psoriasis Foundation’s Psoriasis Prevention Initiative (PPI). To learn more about the CP3 Study, please refer to this link 

- Light Treatment Effectiveness (LITE) Study, which investigates the effects of narrow-band ultraviolet B phototherapy on psoriatic plaques. To learn more about the LITE Study, please refer to this link 

-Vascular Inflammation in Psoriasis trials (VIP), which are multi-center trials that will determine the impact of psoriasis treatment on novel biomarkers of cardiometabolic disease. To learn more about the VIP Studies, please refer to this link.

-Incident Health Outcomes and Psoriasis Events (iHOPE) Study, a study of 9000 psoriasis patients which evaluates how body surface area of skin involvement influences risk of cardiovascular disease. To learn more about the iHope Study, please refer to this link 



Welcome to our newest members of the team! Read more about them on our Team page! 

Brooke Hefele: lead PCORI/LITE Coordinator.

Maha Syed: lead VIP and AD Coordinator.

Jennifer Mason: lead G5P and Acne Coordinator. 

Basma Malik: lead PSBiobank and RASH Coordinator.

In the News: 

April 9th, 2021:

October 25th, 2020:

November 27th,2019: Management and Treatment of Psoriasis with Phototherapy

November 26th, 2019: New psoriasis treatment uses light therapy, how to get in on the study

Please be patient with us, while our website goes through some new and exciting changes! :) 


Where's the Gelfand Lab? Find our bus ads throughout the streets of Philadelphia!